drugset
drugset / Trial / NCT06846398

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398 ↗

Phase 2 Active not recruiting 25 enrolled Shanghai Argo Biopharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase 2 in Adult Subjects with Hereditary Angioedema

Timeline

Start
2025-02-28
Primary completion
2026-06-30
Completion
2028-03-30

Outcome

Met primary endpoint

release “BW-20805 demonstrated substantial reductions in monthly HAE attack rates across all treatment groups in the primary endpoint analysis population (n=24).” argobiopharma.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject BW-20805 Unknown 300 mg Subcutaneous
Subject BW-20805 Unknown 600 mg Subcutaneous

Indications

hereditary angioedema